[Comparison of primary tongue carcinoma with second primary tongue carcinoma after radiotherapy for nasopharynx cancer].
OBJECTIVE
To investigate the clinical characteristics and prognosis of second primary tumor of tongue (SPTr) after nasopharyngeal carcinoma (NPCR) treated with radiotherapy.


METHODS
Clinical data of 53 patients with SP7T after NPCR (group A) and 252 patients with primary tongue carcinoma (group B) were analyzed retrospectively with regard to clinical characteristics and survival rate (Kaplan-Meier); and multivariate analysis was performed using Cox proportional hazards model.


RESULTS
There was no significant difference between group A and group B ( P > 0. 05) in the presenting age, sex, tumor size, cTNM stage, tumor differentiation and the rate of distant metastasis. The overall 5-year survival rates were 41.6% in group A and 56.3% in group B (chi2 = 4.40, P = 0.0359) with a statistically significant difference between two groups. The differences of tumor location (chi2 = 61.18, P = 0.000) and rate of clinical (cN+, chi2 = 6.846, P = 0.009) or pathological lymph node metastasis (pN+, X2 = 3.993, P = 0.046) were also statistically significant between group A and group B, respectively. Multivariate analysis showed that age at presence, cTNM stage and with or without neck lymph node dissection were independent risk factors affecting survival.


CONCLUSIONS
Second primary tongue carcinoma after radiotherapy for nasopharyngeal carcinoma is likely to occur on the dorsal aspect of the tongue with worse prognosis but with a lower rate of lymph node metastasis than that of primary tongue carcinoma. However, radiotherapy history is not an independent influencing factor on prognosis. Surgical resection or combined modality therapy may give a better prognosis.
Sun
Chuan-zheng
CZ
State Key laboratory of Oncology in Southern China, Departmemt of Head and Neck Surgery, Cancer Center, SUN Yat-sen University Guangzhou, China.
Chen
Fu-jin
FJ
Zeng
Zong-yuan
ZY
Li
Qiu-li
QL
Chen
Yan-feng
YF
Song
Ming
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D005927:Glossectomy / Q000379:methods; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009303:Nasopharyngeal Neoplasms / Q000532:radiotherapy*; D037981:Neck Dissection; D009381:Neoplasms, Radiation-Induced / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D016016:Proportional Hazards Models; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D014062:Tongue Neoplasms / Q000209:etiology / Q000473:pathology* / Q000628:therapy
D000970:Antineoplastic Agents